cyrilzakka/clinical-trials huggingface dataset:
Early Antiviral Responses to Rhinovirus Infection in Asthma

The bulk of the morbidity and mortality related to asthma is during periods of acutely increased symptomatology called 'exacerbations'. Roughly half of asthma sufferers experience such an exacerbation each year. Most of these events are triggered by viral infections, usually the common cold virus (rhinovirus).

A key part of the body's defence against viral infections is to produce antiviral proteins called 'interferons', which have a myriad of effects to stop viruses. Previous work on cells taken from volunteers with asthma and healthy controls and infected with rhinovirus in the lab suggests interferon production is impaired in asthma. However when human volunteers with asthma are infected with rhinovirus, high levels of interferon are found a few days later - along with high numbers of virus. Whether the high virus numbers are the result of an initially weak interferon response, with subsequently unchecked viral replication leading to exaggerated interferon levels, is unknown as no one has measured interferons early in infection.

By infecting volunteers with asthma and healthy controls with rhinovirus at a known time, only done in a handful of centres worldwide, we will be able to measure interferons within hours of infection and well before symptoms develop.


Eligibility Criteria:
For Asthma group:

Inclusion Criteria:

* Age 18-55 years
* Doctor diagnosis of asthma
* Previous asthma exacerbation

Exclusion Criteria:

* Smoking history over past 12 months
* Sinonasal disease, including current symptoms of allergic rhinitis
* Asthma exacerbation or an upper respiratory viral infection within the previous six weeks
* Current or concomitant use of oral steroids, monoclonal antibodies or nasal sprays
* Neutralising antibodies to rhinovirus (RV)-16
* Clinically significant diseases other than asthma which, in the opinion of the investigator, may either put the patient at risk because of participation in the study, influence the results of the study, an/or the patient's ability to take part in it
* Inability to understand written or verbal information in English

For healthy control group:

Inclusion Criteria:

• Age 18-55 years

Exclusion Criteria:

As for Asthma group and in addition:

• History of asthma
Treatment of Type-1 Hepatorenal Syndrome Associated With Sepsis

Type 1 Hepatorenal syndrome (type-1 HRS) is a severe complication of patients with advanced cirrhosis characterized by marked renal failure and is associated with a very poor prognosis. Type-1 HRS is often precipitated by a bacterial infection, though it may occur spontaneously. It has been demonstrated that vasoconstrictor agents plus albumin are effective in the reversal of the renal failure. A large number of studies have shown that terlipressin improves renal function in patients with type 1 HRS; treatment is effective in 50-75% of patients approximately. Currently there are no specific studies about the treatment of type-1 HRS with ongoing infections.

All consecutive patients with cirrhosis hospitalized with an infection or who developed an infection during hospitalization for an acute decompensation of the disease in four university hospitals.

Criteria for inclusion were: 1/ cirrhosis as diagnosed by liver biopsy or a combination of clinical, biochemical, ultrasonographic, and/or endoscopic findings; 2/ age between 18 and 80 years; 3/ presence of sepsis, as defined by infection and signs of Systemic Inflammatory Response Syndrome; and 4/ occurrence of type-1 HRS during the infection, as defined by standard diagnostic criteria. Exclusion criteria were: 1/ hepatocellular carcinoma outside the Milan criteria; 2/ any severe extrahepatic condition, including cardiovascular, neurological, and organic kidney diseases; 3/ septic or hypovolemic shock; 4/ terminal condition (death expected in less than 48 hours); and 5/ lack of informed consent.

Aim: A proof of concept study to evaluate whether treatment with terlipressin and albumin in the course of an infection associated with type-1 HRS is effective and safe.

Eligibility Criteria:
Inclusion criteria:

* Cirrhosis as diagnosed by liver biopsy or a combination of clinical, biochemical, ultrasonographic, and/or endoscopic findings.
* Age between 18 and 85 years.
* Presence of sepsis, as defined by active infection, and signs of Systemic Inflammatory Response Syndrome.
* Occurrence of type-1 HRS during the infection, as defined by standard diagnostic criteria.

Exclusion criteria:

* Hepatocellular carcinoma outside the Milan criteria.
* Any severe extrahepatic condition, including cardiovascular, neurological, and organic kidney diseases.
* Septic or hypovolemic shock.
* Terminal condition (death expected in less than 48 hours).
* Lack of informed consent.
Prevalence of Asthma and Allergies Among Children in UAE

Multicenter, cross-sectional study to recruit a random sample of 6000 children via school class registers: 3000 children aged 13-14 years and 3000 children aged 6-7 years.

Multicenter, cross-sectional study to recruit a random sample of 6000 children via school class registers: 3000 children aged 13-14 years and 3000 children aged 6-7 years.Standard ISAAC core questions for wheezing, rhinitis, and atopic dermatitis will be used. The ISAAC questionnaire has been validated by the World Health Organization and translated into many languages, and used in many countries. In this study, the Arabic and English version will be used. In addition, questions regarding exposure to Arabian incense "Bokhor" and smoking questions of the environmental questionnaire will be included.

ISAAC Questionnaires

1. Core questionnaire on wheezing.
2. Core questionnaire on rhinitis.
3. Core questionnaire on atopic dermatitis.
4. Smoking questions of the environmental questionnaire.
5. Video questionnaire on wheezing (only for 13-14 years age group, if applicable)

Eligibility Criteria:
Inclusion Criteria:

* Children with age 6 to 7 years or with age 13 to 14 years at the time of questionnaires completion, and residing in Dubai and the Northern Emirates of UAE.
* Children aged 6 to 7 years or 13 to14 years, whose legal guardians give their consent.
* Able to give assent in the 13 to 14 years group.
* Able to comprehend and answer the questionnaire themselves in the 13 to 14 years group.

Exclusion Criteria:

* Aged 13 to 14 years and unable to answer the questionnaire due to physical or mental disability.
* Parent or legal guardian refuses sign and return consent for the 6 to 7 years group and the 13 to 14 years group.
Contact Lens Optics and Visual Performance

This study will evaluate changes in visual performance at different pupil sizes between a single vision soft contact lens and multifocal soft contact lens, and compare refractive error measured between these two lenses with an autorefractor and an aberrometer


Eligibility Criteria:
Inclusion Criteria:

* Able to read and understand the informed consent document
* 18 to 39 years of age (inclusive)
* Best corrected visual acuity of 20/25 or better in the right eye
* Refractive error from -1.00D to -8.00D with astigmatism less than or equal to -1.00D in the right eye (corneal plane)

Exclusion Criteria:

* Any ocular or systemic conditions affecting vision, refraction, or the ability to wear a soft contact lens
* History of ocular trauma or surgery causing abnormal or distorted vision
* Current Rigid Gas Permeable (RGP) contact lens wearers
* Pregnant and/or lactating females, by self-report
Propofol Versus Volatile Anesthesia in Post Operative Pain Management

The study will test the hypothesis that patients anesthetized with propofol suffer less postoperative pain than those anesthetized with sevoflurane.

Patients undergoing s stripping operation for varicose veins will be randomized to one of two groups. Group 1 patients will receive propofol anesthesia. Group 2 patients will receive sevoflurane anesthesia. Intraoperative measurements including mean-arterial pressure, heart rate, propofol infusion rate, remifentanil infusion rate, and end-tidal sevoflurane concentration will be taken at 15 minute intervals. Patients in both groups will receive Piritramid as necessary to control pain either intravenously or through patient controlled pump. VAS pain score, mean-arterial pressure, heart rate, nausea will be evaluated at 30 minute intervals during the first four postoperative hours. Piritramid dosage and vomiting will be recorded through the first postoperative morning. Patients will rate pain based on the VAS score for the period between leaving the recovery room and the first postoperative morning

Eligibility Criteria:
Inclusion Criteria:

* Participants will undergo a stripping operation for varicose veins
* Surgery will be performed by one physician only
* Written informed consent

Exclusion Criteria:

* Any contraindications to the proposed interventions
* Procedures done under regional anesthesia
Integrative Personal Omics Profiling for Dynamic Molecular Phenotypes Monitoring During Fiber Supplementation

The investigators propose a comprehensive, multiomic study that will integrate longitudinal data associating changes in specific gut bacteria and host in response to prebiotic fiber supplementation. These data will guide the development of an integrative biological signature relating bacterial-derived metabolites with biological outcome in the host.

With this study, the investigators propose to assemble a cohort of healthy individuals that will receive prebiotic supplementation, during comprehensive, longitudinal characterization of the microbiota and host changes with clinical markers and multiple omics assays. These multiomic data will then be integrated, generating unique biological signatures that define the role that microbial metabolites from specific bacteria play in host biological activity. Through this study the investigators expect to gain a detailed and clear understanding of the physiological changes, at the mechanistic level, that occur in the microbiome and host in response to dietary supplementation with prebiotic fiber.

Eligibility Criteria:
Inclusion Criteria:

* Good general health

Exclusion Criteria:

* Fasting Blood Sugar \>126 mg/dL
* Triglycerides \>400 mg/dL
* Uncontrolled hypertension
* Vascular disease
* Chronic inflammatory conditions
* Major organ disease
* Heavy alcohol use
* Pregnancy/lactation
* Prior bariatric surgery
* Active psychiatric disease
* Use of medication known to affect carbohydrate or lipid metabolism
* Active eating disorder
The Ventricular Catheter Placement Study: Assessment of Efficacy and Safety of an Ultrasound Guided Shunt Insertion Technique

Shunt failure remains a significant problem in pediatric patients with hydrocephalus. If reliable techniques for the accurate placement of ventricular catheters can be developed, shunt survival may improve. The purpose of this study is to assess the efficacy and safety of the ultrasound guided shunt insertion technique in the hands of experienced surgeons. The primary outcome measure is ventricular catheter location determined from post-operative brain images. The study is being conducted by the Hydrocephalus Clinical Research Network (HCRN), a network established to conduct multi-institutional clinical trials on pediatric hydrocephalus. Pediatric neurosurgeons at HCRN centers enrolled in this study will perform either ultrasound guided shunt surgery or a conventional shunt surgery. Patients who undergo conventional shunt surgery will serve as a contemporary control group.


Eligibility Criteria:
Inclusion Criteria:

* Patients must have clinical and radiographic evidence of hydrocephalus as determined by a pediatric neurosurgeon and require a ventriculoperitoneal shunt (atrial, pleural, gallbladder and other shunt systems are excluded)
* Patients can have no prior history of shunt insertion for hydrocephalus. A history of an external ventricular drain, subgaleal reservoir-catheter, or subgaleal shunt is permissible
* Patients must be less than 18 years of age at the time of shunt insertion

Exclusion Criteria:

* Active CSF or abdominal infection
* Spread of tumor in the subarachnoid space documented on enhanced imaging (CT or MRI) of the head or spine
* CSF leak without hydrocephalus
* Pseudotumor cerebri
* Dandy-Walker malformation or arachnoid cyst as a cause of hydrocephalus
* Loculations within the ventricular system
* Hydranencephaly, alobar holoprosencephaly or any other congenital anomaly of the brain that severely distorts the ventricular anatomy such that ventricular catheter location cannot be determined
* Other systemic disorders that would preclude the insertion/revision of a ventricular shunt
* Other difficulties that would preclude follow-up at one year (e.g. terminal illness with life expectancy less than 1 year)
Incidence of Perioperative Cerebrovascular Stroke in Assuit University Hospitals , Hospital Based Study

Stroke is the most common cause of disability in elderly people (over 65years of age) and the third most common cause of death in the world . The World Health Organization estimates that one in six people globally will suffer from stroke in their lifetime.

Perioperative stroke is the most unwanted complication for patients, as well as for surgeons and anesthesiologists . The reported risk of perioperative stroke varies with the type of surgery. Its incidence is generally not high (approximate 0.1-1.9%) in non-cardiac, non-neurologic, and non-major surgery However, it may occur in up to 10% of patients undergoing high-risk cardiac or brain surgery . Patients with perioperative stroke are less likely to have a good functional outcome and have an eight-fold higher mortality compared with those without perioperative stroke


Eligibility Criteria:
Inclusion Criteria:

1. all Patients admitted to General surgery, cardiothorasic surgery and vascular surgery Depatments in assuit university hospitals during one year that will going to operation
2. ALL age Groups .
3. Both Sex.

Exclusion Criteria:

* Other surgical departments
* Patients with Syptoms that related to delayed recovery from anaesthesia .
Quantification of Dynamic and Static Cerebral Autoregulation (CA) Under Anaesthesia

Cerebral autoregulation (CA) is the mechanism by which the brain vasculature maintains constancy of cerebral blood flow (CBF). Reliable direct measurements of CBF at different blood pressure levels are difficult because they are invasive and time-consuming. This type of measurement to quantify CA is generally referred to as static cerebral autoregulation (sCA). Alternatively, it is possible to measure CA indirectly from blood pressure oscillations. Dynamic cerebral autoregulation (dCA) measures how quickly the cerebral vessels react to a change in blood pressure to normalize CBF. Since the introduction of transcranial Doppler ultrasound (TCD), it has become possible to estimate CBF velocity relatively easy, which in turn correlates well with CBF changes. This method is widely used to quantify dCA. However, it is not clear how sCA correlates with dCA over a range of physiologic mean blood pressure (MBP). It is important to compare different methods of assessing CA, because impaired CA may result in increased risk of perioperative complications such as stroke. In this study, the investigators were interested in establishing the relationship between sCA and dCA during surgery under general anesthesia. The investigators aim to compare these methods during propofol and sevoflurane anesthesia.


Eligibility Criteria:
Inclusion Criteria:

* ASA-I or ASA-II, willing and able to give written informed consent, scheduled for elective, non-cardiothoracic surgery under general anaesthesia and age 18 years and above.

Exclusion Criteria:

* Patient related

  * Unable/ unwilling to participate
  * ASA-III or higher
  * Age \< 18 years
  * History of: uncontrolled hypertension, diabetes, Parkinson's disease, uncontrolled cardiac arrhythmia, Pure autonomic failure (formerly called idiopathic orthostatic hypotension), Multiple system atrophy with autonomic failure (formerly called Shy-Drager syndrome), Addison's disease and hypopituitarism, pheochromocytoma, peripheral autonomic neuropathy (e.g., amyloid neuropathy, idiopathic autonomic neuropathy), known cardiomyopathy, extreme left ventricle hypertrophy or ejection fraction \< 30%, proven or suspected allergy for any of the medication used during induction of anaesthesia, malignant hyperthermia.
  * Unability to record transcranial Doppler ultrasound due to anatomical variance (\~5% of population)
  * Contra-indications for intravenous or inhalational anaesthesia.
  * Contra-indications for phenylephrine: severe hypertension, peripheral vascular illness, severe hyperthyroidism
  * Simultaneous use of MAO-inhibitors, dopaminergic or vasoconstrictor ergot alkaloids (bromocriptine, cabergoline, pergolide, ergotamine, methylergometrine, methysergide), linezolid, tricyclic antidepressants, serotonin-norepinephrine reuptake inhibitors, digoxin, quinidine, oxytocin.
* Surgery related

  * Day case surgery
  * Laparoscopy with CO2 insufflation
  * Extreme positioning during surgery (head-down/up tilt, lateral decubitus position, prone)
  * Surgery \< 60 minutes.
Study of XL184 (Cabozantinib) in Adults With Advanced Malignancies

The purpose of this study is to determine the best and safest dose of XL184 administered orally. XL184 is a new chemical entity that inhibits VEGFR2, MET and RET, kinases implicated in tumor formation, growth and migration. To determine the highest safe dose, subjects will receive different amounts of the drug. The first group of subjects will receive the lowest dose of XL184. As long as no medically unacceptable side effects are noted, the dose will be increased for the next group. When the maximum tolerated dose (MTD) is reached, at least 20 subjects with Medullary Thyroid Cancer (MTC) will be enrolled to evaluate the effect of XL184 in this population.


Eligibility Criteria:
Inclusion Criteria:

* Histologically confirmed advanced malignancy (solid tumor or lymphoma) that is metastatic or unresectable for which standard curative measures do not exist or are no longer effective
* Eastern Cooperative Oncology Group (ECOG) performance status \</= 2
* Life expectancy greater than 3 months
* Adequate organ and marrow function
* Written informed consent
* Use of acceptable methods of contraception during the course of the study and for 3 months after completion of study
* In the MTD expanded cohort: at least 20 subjects with metastatic and/or advanced/locally recurrent Medullary Thyroid Cancer not appropriate for surgical resection with measurable disease as defined by RECIST

Exclusion Criteria:

* Chemotherapy, immunotherapy or radiation within 4 weeks (or nitrosoureas or mitomycin C within 6 weeks) before the first scheduled dose of XL184
* Administration of an investigational drug within 30 days of the first dose of XL184
* Subject has not recovered from adverse events due to investigational agents or other medications administered more than 4 weeks before study enrollment
* Known brain metastases
* Uncontrolled intercurrent illness
* Pregnancy or breastfeeding
* Known HIV positive
* Known allergy or hypersensitivity to any of the components of the XL184 formulation
FTO Gene Variants and Diet in Obesity

Studies have shown that the effect of fat mass and obesity-associated (FTO) gene on obesity is modulated by lifestyle factors. Hence, we aimed to determine whether two single nucleotide polymorphisms (SNPs) in the FTO gene are associated with obesity and to assess whether these associations were modified by lifestyle factors. The study included 200 obese and 200 non-obese individuals from Turkey. Our study suggests that the effect of the SNPs on obesity traits is likely to be influenced by lifestyle factors in this Turkish population.


Eligibility Criteria:
Inclusion Criteria:

1. attending routine outpatient visits,
2. aged 24 to 50 years,
3. having a BMI ≥ 18.50 kg/m2
Effects of the Visual Stimulation on the Motor and Visual Cortex in Migraneurs With and Without Aura

The aim of this study is to investigate the motor and visual cortex excitability in response to visual stimulation of migraineurs with and without aura compared to healthy individuals. For this purpose, electrical cortical activity of migraineurs will be compared to healthy volunteers.

A cross sectional study to compare the best approach to migraineurs evaluation. For this, healthy individuals, after reading and signing the free and informed consent will be submitted to a single session to obtain the normal neurophysiological endpoints and thus compare with those obtained in individuals with migraineurs volunteers. All volunteers (healthy and migraineurs) will be submitted to a neurophysiological evaluation through transcranial magnetic stimulation (TMS) and electroencephalography (EEG). A visual stimulation will be delivered during the assessment of habituation through visual evoked potential volunteers (VEP-habituation) and the following measures will be evaluated before and after visual stimulation: (i) Motor Evoked Potentials (MEP); (ii) Motor Threshold (MT); (iii) Short Interval Cortical Inhibition (SICI); (iv) Intracortical Facilitation (lCF) and (v) Phosphene Threshold (PT).

Eligibility Criteria:
Inclusion Criteria:

* Ages: 18-55 years
* Gender: Both
* Prior headache report

Exclusion Criteria:

* Pregnant women;
* Pacemaker;
* History of seizures;
* Metallic implants in the head;
* Patients with clinical evidence of brain injuries;
* Chronic pain associated to others diseases;
* Use of neuroleptic medications
Manual Lymphatic Drainage vs Marian Clark Drainage in Pcs

Pelvic congestion syndrome is a debilitating and potentially life threatening disorder of the pelvic region there is a constant hindrance in patient's daily professional and personal life due to the chronic pain. it can provide a definite way to improve pelvic congestion and quality of life. In this way it can benefit a large percentage of community females suffering from pelvic congestion syndrome and disability. This can grow at large length in favour of patients, clinicians and overall women health.

As per researcher's knowledge there are limited researches in which efficacy of manual lymphatic drainage in pelvic congestion syndrome are analyzed furthermore my comparative intervention i.e Marian Clark drainage is a rarely used osteopathic technique and not much studies have been conducted on it. This study helped to in identifying the effect of manual lymphatic drainage versus Marian Clark drainage on pain and disability in patients with pelvic congestion syndrome.

Eligibility Criteria:
Inclusion Criteria:

* Multiparous women
* Age ranging 20 to 50
* Ovarian veins \>4mm in diameter on Ultrasound Chronic pelvic pain/pressure for more than 6 months.
* Dull, aching or "dragging" pain in the pelvis or lower back, particularly on standing and worse around the time of your menstrual period.
* Pelvic pain that worsens as the day goes on, particularly if much time is spent standing dyspareunia
* Swollen veins in pelvic region, butt, thighs, vulva and vagina.
* Associated Irritable bladder/Irritable bowel present

Exclusion Criteria:

* Pelvic pain due to other organic cause like uterine fibroids, Endometriosis, Ovarian cyst pelvic pain due to neurological or musculoskeletal disorder
* Uterine prolapse
* Pelvic cancer